Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial
- 6 February 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Clinical Oncology
- Vol. 20 (5), 905-912
- https://doi.org/10.1007/s10147-015-0790-y
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS TrialJapanese Journal of Clinical Oncology, 2013
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2012
- Gastrointestinal stromal tumours: origin and molecular oncologyNature Reviews Cancer, 2011
- A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GISTCancer Treatment Reviews, 2011
- Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity ProfilesOncology, 2011
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInternational Journal of Cancer, 2010
- Gastrointestinal stromal tumor: a bridge between bench and bedsideGastric Cancer, 2009
- A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and SafetyJapanese Journal of Clinical Oncology, 2009
- Gastrointestinal stromal tumors in Iceland, 1990–2003: The Icelandic GIST study, a population‐based incidence and pathologic risk stratification studyInternational Journal of Cancer, 2005
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005